Until last week, federal law prohibited marijuana users from owning or possessing firearms, even in states where marijuana is legal. In recent years, we have covered the differing opinions by federal courts challenging this status quo. On June 18, 2026, the Supreme Court held in a 9-0 decision in U.S. v. Hemani that 18 U.S.C.
On April 28, 2026, Acting Attorney General Blanche (“AG”) issued a notice of hearing concerning the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). The notice replaced the hearing that began in December 2024 (“2024 Hearing”), which the AG terminated upon issuing the new notice. The
The Washington State Liquor and Cannabis Board (LCB) published an interesting bulletin this Tuesday, June 16th. The bulletin finds that DEA’s final rule on medical marijuana rescheduling “does not appear to apply to Washington’s cannabis licensees, due to the statutory framework predominantly regulating recreational cannabis.” The word “predominantly” is doing a lot of work in
Harris Sliwoski attorney Jason Adelstone will present at the International Cannabis Bar Association’s (INCBA) Cannabis Law Institute 2026, taking place June 17–18 in Chicago and hosted by Northwestern Pritzker School of Law. Jason will join Adi Rozenfeld of Herzog Fox & Neeman and Sahar Ayinehsazian of A.Y. Strauss for a panel discussion titled: Beyond Borders:
With just over two weeks until DEA’s expedited processing deadline for state legal operators to apply for DEA registration, several petitioners litigating the legality of the DEA’s final rule have filed a motion to stay DEA’s final rule in the D.C. Circuit (“Motion”). The Motion was brought by the National Drug and Alcohol Screening Association,
On May 22, the states of Nebraska, Indiana, and Louisiana filed a Petition for Review in the United States Court of Appeals for the District of Columbia Circuit (“DC Circuit”) challenging the Acting Attorney General’s (“AG”) final agency action moving FDA-approved and state-licensed marijuana into Schedule III of the Controlled Substances Act (“CSA”). The DC
Since acting Attorney General Todd Blanch announced that state-legal medical marijuana would move to Schedule III, the commentary has been relentless — hot takes, doomsayers, and self-proclaimed experts flooding LinkedIn with conflicting interpretations. Much of it is speculative, overstated, and uneducated. This piece cuts through the noise and responds to the questions I have fielded
For state-licensed medical marijuana operators, a narrow and potentially transformative window has opened–one that could position your business for future interstate and even global trade. While the Acting Attorney General’s rescheduling order is likely to face legal challenges, the immediate reality is this: you have a 60-day opportunity to act. As of yesterday, April 28,
The DOJ Final Order on marijuana rescheduling dropped last week. Acting Attorney General Todd Blanche ordered that “FDA-approved drug products containing marijuana, as well [as] marijuana in any form covered by a state medical marijuana license, be placed in schedule III of the CSA.” The Order went further than many of us anticipated. It also
U.S. joins much of the world in acknowledging medical marijuana The U.S. has joined much of the world in acknowledging medical marijuana. Let international trading begin! Effective April 28, 2026, the acting Attorney General “hereby order[s] that FDA-approved drug products containing marijuana, as well marijuana in any form covered by a state medical marijuana license,
